{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T19:21:42Z","timestamp":1695496902496},"reference-count":68,"publisher":"Informa Healthcare","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1517\/13543784.10.7.1255","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T19:34:27Z","timestamp":1115235267000},"page":"1255-1264","source":"Crossref","is-referenced-by-count":3,"title":["Development of agents for the treatment of systemic sclerosis"],"prefix":"10.1517","volume":"10","author":[{"given":"Ariane L","family":"Herrick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2005,2,24]]},"reference":[{"key":"CIT0001","first-page":"2159","volume":"26","author":"MEDSGER TA","year":"1999","journal-title":"Rheumatel"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1053\/berh.1999.0075"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380309"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.1.39"},{"key":"CIT0006","first-page":"457","volume":"31","author":"BRENNAN P","year":"1992","journal-title":"BLACK C etal.,ON BEHALF OF THE UK SCLERODERMA STUDY GROUP: Reliability of skin involvement measures in scleroderma. Br. j Rheumatel"},{"key":"CIT0007","first-page":"1281","volume":"22","author":"CLEMENTS P","year":"1995","journal-title":"E SEIBOLD J et al.: Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. j Rheumatel"},{"key":"CIT0008","first-page":"299","volume":"42","author":"BLACK CM","year":"1999","journal-title":"HERRICK ALet al.: Interferon-a does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo controlled trial. Arthritis Rheum."},{"key":"CIT0010","first-page":"1194","volume":"42","author":"CLEMENTS PJ","year":"1999","journal-title":"WONG W- K et al.: High-dose versus low dose D-penicillamine in early diffuse systemic sclerosis. Arthritis Rheum."},{"key":"CIT0013","first-page":"871","volume":"132","author":"SEIBOLD JR","year":"2000","journal-title":"A randomized, double-blind, placebo-controlled trial. Ann. Int. Med."},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70246-X"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)79828-7"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.10.992"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.8.865"},{"key":"CIT0019","first-page":"75","volume":"36","author":"CLEMENTS PJ","year":"1993","journal-title":"STERZ M etal.: Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum."},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199811000-00012"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-12-200006200-00004"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199912)42:12<2638::AID-ANR20>3.0.CO;2-X"},{"key":"CIT0024","first-page":"425","volume":"132","author":"BADESCH DB","year":"2000","journal-title":"A randomized, controlled trial. Ann. IrM Med."},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801293380501"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(99)00008-0"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199801)184:1<4::AID-PATH968>3.0.CO;2-0"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.20.15220"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90009-R"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02460.x"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)60391-1"},{"key":"CIT0033","first-page":"635","volume":"25","author":"ANONYMOUS","year":"2000","journal-title":"Drugs Fut."},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199912150-00027"},{"key":"CIT0035","first-page":"321","volume":"338","author":"FISHMAN AP","year":"1998","journal-title":"N Engl. I Med."},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.9.952"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-6980(99)00060-X"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00494-5"},{"key":"CIT0042","first-page":"1866","volume":"342","author":"HOEPER MM","year":"2000","journal-title":"EHLERDING S etal.: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl. I Med."},{"key":"CIT0045","first-page":"258","volume":"94","author":"MANCINI GB","year":"1996","journal-title":"The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.12.1388"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T"},{"key":"CIT0049","first-page":"455","volume":"17","author":"NOBLE NA","year":"1997","journal-title":"Nephrol"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1373.1999.d01-88.x"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.23.1.f192"},{"key":"CIT0052","first-page":"1268","volume":"21","author":"VANCHEESWARAN R","year":"1994","journal-title":"j Rheumatol"},{"key":"CIT0053","first-page":"831","volume":"151","author":"ABRAHAM DJ","year":"1997","journal-title":"Am. J. Pathol"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1007\/s100670050132"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.4.411"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.82.4.505"},{"key":"CIT0058","first-page":"331","volume":"1","author":"KENTSCH M","year":"1999","journal-title":"The therapeutic potential of endopeptidase inhibitors. Drugs RD"},{"key":"CIT0059","first-page":"314","volume":"25","author":"YAMAMOTA T","year":"1998","journal-title":"Rheumatol"},{"key":"CIT0060","first-page":"273","volume":"189","author":"COTTON SA","year":"1999","journal-title":"Foam]"},{"key":"CIT0061","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1152\/physrev.2000.80.4.1337","volume":"80","author":"HAMPL V","year":"2000","journal-title":"Physiol Rev"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.22.2429"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)65068-4"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.7.636"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)64133-5"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04095-7"},{"key":"CIT0068","first-page":"2389","volume":"26","author":"KHAN E BELCH JJF","year":"1999","journal-title":"j Rheumatol"},{"key":"CIT0069","first-page":"4","volume":"19","author":"HERRICK AL","year":"2001","journal-title":"Clin. Exp. Rheumatol"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.4.309"},{"key":"CIT0071","first-page":"349","volume":"18","author":"HERRICK AL","year":"2000","journal-title":"Clin Exp. Rheumatol"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(94)90444-8"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00419-2"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(200002)190:3<330::AID-PATH588>3.0.CO;2-4"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.11.e73"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.1.84"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10310-X"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.7.1479"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199905000-00003"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.6.577"},{"key":"CIT0084","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200005)43:5<1054::AID-ANR14>3.0.CO;2-W"},{"key":"CIT0086","first-page":"294","volume":"317","author":"UK SCLERODERMA STUDY GROUP","year":"1998","journal-title":"How can treatment of systemic sclerosis be improved? BMJ"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.10.7.1255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,17]],"date-time":"2019-02-17T22:18:54Z","timestamp":1550441934000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.10.7.1255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":68,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2005,2,24]]},"published-print":{"date-parts":[[2001,7]]}},"alternative-id":["10.1517\/13543784.10.7.1255"],"URL":"https:\/\/doi.org\/10.1517\/13543784.10.7.1255","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}